Words by ITV News journalist Sanjay Jha
The vaccine candidate is being developed by Oxford University and AstraZeneca. In India, the trial is being conducted by the Serum Institute of India.
On Tuesday, AstraZeneca said the vaccine trial would stop, as a precautionary measure, after a patient in the UK reported a side effect.
As a result, India’s official drug regulator issued a notice to the Serum Institute of India to pause its trials of the Oxford-AstraZeneca coronavirus vaccine.
"We are reviewing the situation and pausing India trials till Astrazeneca restarts them," the Serum Institute of India tweeted on Thursday.
Just the day before, the company said it had not faced any issues in its trials so far and that it would continue its studies.
The Oxford-AstraZeneca vaccine, which is undergoing Phase 3 clinical trials at more than 60 locations in the US, Brazil and South Africa, has been cleared for combined Phase 2 and Phase 3 trials in India.
Phase 3 of the human trial was scheduled to begin next week upon 1,600 volunteers across 20 sites in India.
The trials in India began last month and about 100 participants have received the dose.